Please assess the completion status of the following clinical trial:

Trial Title: Pentoxifylline Role Against Chemotherapy-induced Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients\> 18 years old.~* Female patients Breast cancer patients who received paclitaxel-based regimen for 12 weeks.~* Eastern Cooperative Oncology Group (ECOG) performance ≤ 2-Adequate bone marrow function.~* Adequate liver and kidney function.~Exclusion Criteria:~* Children less than 18 years old.~* Evidence of physical diseases or major surgery.~* Patientswith a history of chronic diseases including; renal, hepatic, gastrointestinal, respiratory, hematological, and metabolic or other diseases.~* Patients with preexisting clinical neuropathy.~* Patients with diabetes mellitus.~* Metastatic breast cancer.~* Patients receiving medications that ameliorate neuropathy like; antidepressants, anticonvulsants, opioids, adjuvant or topical analgesics.~* Patients treated with medications that increase the risk of neuropathy.~* Hypersensitivity to pentoxifylline or xanthine derivatives.~* Patients retinal bleeding or active peptic ulcer.~* Patients at high risk for bleeding or taking medications that increase risk of bleeding.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- PTX group (Type: ACTIVE_COMPARATOR): paclitaxel based regimens plus Pentoxifylline 400mg twice daily for 12weeks.
- Control group (Type: PLACEBO_COMPARATOR): include those assigned for Taxol-based chemotherapy without intervention for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).